Every 8-K that Seres Therapeutics Inc (MCRB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MCRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCRB filings page.
Seres Therapeutics reported second-quarter 2026 grant revenue of $736,000 and net income of $4.6 million, compared with a $19.9 million loss a year earlier. Results included a $25.0 million gain from the VOWST business sale and $22.0 million of operating expenses, including a $5.8 million impairment.
The company ended June 30, 2026 with $15.6 million in cash and cash equivalents and, together with milestone termination payments from Nestlé, expects to fund operations into the first quarter of 2027. Seres highlighted encouraging SER-155 data in irEC, is evaluating Phase 2 development, pursuing partners and capital, and further reducing facility lease obligations.
Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC to reduce facilities costs and primary restoration obligations at 200 Sidney Street in Cambridge. The company will surrender about 21,295 rentable sq ft and retain about 47,341 rentable sq ft, with the remaining lease term shortened from January 13, 2031 to December 31, 2026.
As consideration, Seres will increase a letter of credit by about $2.2 million to a total of about $3.6 million to be applied to rent and operating expenses, pay a deferred termination amount of $3.85 million by January 4, 2027, and issue 103,520 shares of common stock at $4.83 per share (total $500,001.60) under an existing Form S-3 shelf registration. The shares will be freely tradeable when issued; if their issuance-date market value is below $500,000, Seres must pay the landlord the cash difference.
Seres Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders, where all proposals were approved after the meeting was reconvened due to an earlier lack of quorum. Stockholders approved an amendment and restatement of the 2025 Incentive Award Plan, increasing the shares of common stock available for issuance under the plan by 900,000 shares, enabling continued use of equity-based compensation.
A total of 4,985,176 shares, representing approximately 51.75% of shares outstanding as of the April 13, 2026 record date, were represented in person or by proxy. Three Class II directors were elected to serve until the 2029 Annual Meeting, the appointment of PricewaterhouseCoopers LLP as independent auditor for 2026 was ratified, executive compensation was approved on an advisory basis, and an adjournment proposal was approved but ultimately not needed.
Seres Therapeutics reported early clinical data showing promising activity for its live biotherapeutic SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC). In an investigator-sponsored trial at Memorial Sloan Kettering, 80% of 15 patients achieved an immunosuppressive-free clinical response of diarrhea by Day 15, and 33% reached complete remission, with SER-155 generally well tolerated and no drug-related serious adverse events.
The company also highlighted prior Phase 1b allo-HCT results where SER-155 was associated with a 77% relative risk reduction in bacterial bloodstream infections (10% vs 43% on placebo) and significant reductions in systemic antibiotic use. Seres is positioning SER-155 for both irEC and allo-HCT, advancing SER-603 for inflammatory bowel disease and preclinical candidate SER-147 for cirrhosis-related infections. The company reported approximately $29 million in cash and cash equivalents as of March 31, 2026, expects its cash runway to extend into Q1 2027, and has agreed to receive $25 million from Nestlé Health Science in 2026 to buy out future VOWST sales-based milestones, while actively seeking additional partnerships and financing.
Seres Therapeutics entered two agreements aimed at improving its finances and extending its operating cash runway well into the first quarter of 2027.
An amendment with Nestlé Health Science replaces potential future VOWST™ sales milestones with a one-time $25 million payment to Seres in two $12.5 million installments in July and October 2026. Separately, a lease amendment for its Cambridge facility surrenders space, lowers rent and building cost share, and is expected to reduce long-term lease obligations, partly offset by termination fees and use of an existing letter of credit.
Seres reported $29.8 million in cash and cash equivalents as of March 31, 2026 and, reflecting these actions and current plans, now expects to fund operations well into the first quarter of 2027 while advancing programs such as SER-155.
Seres Therapeutics, Inc. reported a governance change with the resignation of board member Hans-Juergen Woerle, M.D., Ph.D. On May 30, 2026, he notified the company that he would step down from the board and its committees, effective May 31, 2026. The company states that his departure is not due to any disagreement regarding operations, policies, or practices.
Seres Therapeutics reported first quarter 2026 results showing a return to operating losses as it invests in its microbiome pipeline. Revenue was modest at $358,000, all from grants, while operating expenses totaled $21.3 million, driven by $13.2 million in research and development and $8.1 million in general and administrative costs.
The company posted a net loss of $19.9 million, compared with net income of $32.7 million a year earlier, when results benefited from a gain on the sale of the VOWST business. As of March 31, 2026, Seres held $29.8 million in cash and cash equivalents and expects this to fund operations through the third quarter of 2026.
Operationally, Seres highlighted an upcoming clinical readout in the coming weeks from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, Phase 2 readiness of SER-155 in allo-HSCT, and IND-enabling progress for SER-603 in inflammatory bowel disease, while actively pursuing partnerships and additional capital.
Seres Therapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for June 9, 2026. Stockholders who hold common shares as of the close of business on April 13, 2026 will be entitled to vote at the meeting.
Because the 2026 meeting will occur more than 30 days after the 2025 meeting anniversary, the company has set a revised deadline for qualified stockholder proposals under SEC Rule 14a-8. Proposals must be received at the company’s principal executive office by the close of business on March 26, 2026 to be considered for inclusion in the 2026 proxy statement.
Seres Therapeutics reported fourth quarter and full year 2025 results and outlined its microbiome pipeline strategy. For 2025, the company generated $0.8 million in grant revenue and recorded $5.7 million in net income from continuing operations, driven largely by an $80.7 million gain on the sale of its VOWST business and lower operating expenses of $94.8 million versus $121.3 million in 2024.
As of December 31, 2025, Seres held $45.8 million in cash and cash equivalents and expects this to fund operations through the third quarter of 2026, while it seeks partnerships and other financing. The company is prioritizing live biotherapeutic programs for inflammatory and immune diseases, including SER-155, which showed a 77% relative risk reduction in bloodstream infections in a Phase 1b allo-HSCT study and is Phase 2 ready, and SER-603 for inflammatory bowel disease. An investigator-sponsored SER-155 trial in immune checkpoint inhibitor–related enterocolitis is fully enrolled, with data expected in the second quarter of 2026.
Seres Therapeutics announced major leadership changes and new pay packages for top executives. The board appointed director Richard N. Kender as Executive Chair and Interim Chief Executive Officer, effective March 2, 2026. Former Co‑CEOs Thomas J. DesRosier and Marella Thorell stopped serving as Co‑Presidents and Co‑CEOs but remain Chief Legal Officer and Chief Financial Officer.
Chief Scientific Officer Matthew Henn adds the role of President, and Kelly Brady becomes Executive Vice President, Chief Operating Officer. Kender will earn a $520,000 base salary, a 55% target bonus, a $250,000 signing bonus, and options on 200,000 shares. Henn’s salary rises to $505,000 with a 45% target bonus, a $230,000 retention bonus, and options on 100,000 shares. Brady’s salary increases to $475,000 with a 45% target bonus, enhanced severance protections, a $230,000 retention bonus, and options on 75,000 shares. Portions of each option grant depend on stockholder approval of an increase to the 2025 Incentive Award Plan at the 2026 annual meeting.
Seres Therapeutics (MCRB) furnished an update via Form 8-K announcing financial results for the quarter ended September 30, 2025 and providing operational updates. The company also shared an updated corporate presentation for investors.
The press release is furnished as Exhibit 99.1 and the investor slide deck as Exhibit 99.2. Consistent with Items 2.02 and 7.01, these materials are furnished, not filed, and are not subject to Section 18 liabilities or incorporation by reference except as expressly stated.
Seres Therapeutics, Inc. is cutting its workforce by approximately 25%, including reductions that took effect in August 2025, as part of a plan to reduce operating costs and extend its available cash. The company expects to incur cash charges of about $1.0 to $1.4 million in the fourth quarter of 2025, primarily for severance.
Based on these cost-saving measures and current operating plans, Seres expects its cash runway to extend into the second quarter of 2026. The company cautions that these expectations rely on current assumptions and are subject to significant risks, including its need for additional funding, its ability to continue as a going concern, its history of losses, and the possibility that the cost savings initiative does not deliver the anticipated benefits.